ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma

BACKGROUND: Many advanced hepatocellular carcinoma (HCC) patients are receiving sorafenib treatment. Sorafenib reportedly improves overall survival (OS) significantly in patients with HCC. Prediction of sorafenib response and prognosis in patients with HCC receiving sorafenib treatment are important...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:World J Gastrointest Oncol
Hlavní autoři: Takaya, Hiroaki, Namisaki, Tadashi, Shimozato, Naotaka, Kaji, Kosuke, Kitade, Mitsuteru, Moriya, Kei, Sato, Shinya, Kawaratani, Hideto, Akahane, Takemi, Matsumoto, Masanori, Yoshiji, Hitoshi
Médium: Artigo
Jazyk:Inglês
Vydáno: Baishideng Publishing Group Inc 2019
Témata:
Observational Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6522768/
https://ncbi.nlm.nih.gov/pubmed/31139312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v11.i5.424
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky